Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-01-01
2008-01-01
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S199100, C435S235100, C435S325000, C435S320100, C536S023720
Reexamination Certificate
active
09458813
ABSTRACT:
Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting and immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.
REFERENCES:
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6264957 (2001-07-01), Collins
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO93/14207 (1993-07-01), None
patent: WO97/06270 (1997-02-01), None
patent: WO97/11093 (1997-03-01), None
patent: WO97/20468 (1997-06-01), None
patent: WO98/02530 (1998-01-01), None
patent: WO98/43668 (1998-10-01), None
patent: WO98/53078 (1998-11-01), None
patent: WO99/02657 (1999-01-01), None
patent: WO99/15631 (1999-04-01), None
Baron et al., “Rescue of Rinderpest Virus from Cloned cDNA,”J. Virol. 71:1265-1271, 1997, Copy Enclosed.
Belshe et al., “Cold Adaptation of Parainfluenza Virus Type 3: Induction of Three Phenotypic Markers,”J. Med. Virol. 10:235-42, 1982.
Blumberg et al., “Measles Virus L Protein Evidences Elements of Ancestral RNA Polymerase,”Virology164:487-497, 1988.
Buchholz et al., “Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter,”J. Virol. 73:251-259, 1999, Copy Enclosed.
Bukreyev, et al., “Recovery of Infectious Respiratory Syncytial Virus Expressing an Additional, Foreign Gene,”J. Virol. 70:6634-41, 1996, Copy Enclosed.
Bukreyev, et al., “Interferon γ Expressed by a Recombinant Respiratory Syncytial Virus Attenuates Virus Replication in Mice Without Compromising Immunogenicity,”Proc. Nat. Acad. Sci. USA96:2367-2372, 1999, Copy Enclosed.
Cadd et al., “The Sendai Paramyxiovirus Accessory C Proteins Inhibit Viral Genoma Amplification in Promoter-Specific Fashion,”J. Virol. 70:5067-74, 1996, Copy Enclosed.
Collins, et al., “Production of Infectious Human Respiratory Syncytial Virus from Cloned cDNA Confirms an Essential Role of the Transcription Elongation Factor from the 5′ Proximal Open Reading Frame of the M2 mRNA in Gene Expression and Provides a Capability for Vaccine Development,”Proc Nat. Acad. Sci. USA92:11563-11567, 1995.
Collins et al., “Parainfluenza Viruses”, inField Virology, B. N. Fields (Knipe et al., eds.), 3rded., vol. 1, p. 1205-1243, Lippincott-Raven Publishers, Philadelphia, 1996.
Conzelmann et al., “Rescue of Synthetic Genomic RNA Analogs of Rabies Virus by Plasmid-Encoded Proteins,”J. Virol. 68:713-719, 1994.
Conzelmann, “Genetic Manipulation of Non-Segmented Negative-strand RNA Viruses,”J. Gen. Virol. 77:381-389, 1996.
Curran, et al., “Sendai Virus P Gene Produces Multiple Proteins from Overlapping Open Reading Frames,”Enzyme44:224-249, 1990, Copy Enclosed.
Curran, et al., “ The Sendai Virus Nonstructural C Proteins Specifically Inhibit Viral mRNA Synthesis,”Virology189:647-656, 1992, Copy Enclosed.
Delenda, et al., “Normal Cellular Replication of Sendai Virus Without thetrans-Frame, Nonstructural V Protein,”Virology228:55-62, 1997, Copy Enclosed.
Delenda et al., “Sendai Viruses with Altered P. V, and W Protein Expression,”Virology242:327-337, 1998, Copy Enclosed.
Dimock, et al., “Rescue of Synthetic Analogs of Genomic RNA and Replicative-Intermediate RNA of Human Parainfluenza Virus Type 3,”J. Virol. 67: 2772-2778, 1993.
Durbin et al., “Minimum Protein Requirements for Transcription and RNA Replication of a Minigenome of Human Parainfluenza Virus Type 3 and Evaluation of the Rule of Six,”Virology234:74-83, 1997.
Durbin et al., “Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA,”Virology235:323-332, 1997.
Finke et al. “Ambisense Gene Expression for Recombinant Rabies Virus: Random Packaging of Positive- and Negative-Strand Ribonucleoprotein Complexes into Rabies Virions,”J. Virol. 71:7281-7288, 1997, Copy Enclosed.
Galinski et al., “Molecular Cloning and Sequence Analysis of the Human Parainfluenza 3 Virus mRNA Encoding the P and C Proteins,”Virology155:46-60, 1986, Copy Enclosed.
Galinski et al., “Molecular Cloning and Sequence Analysis of the Human Parainfluenza 3 Virus Gene Encoding the L Protein,”Virology165:499-510, 1988.
Galinski et al., “RNA Editing in the Phosphoprotein Gene of the Human Parainfluenza Virus Type 3,”Virology186:543-550, 1992.
Garcin et al., “A Highly Recombinogenic System for the Recovery of Infectious Sendai Paramyxovirus from cDNA: Generation of a Novel Copy-back Nondefective Interfering Virus,”EMBO J. 14:6087-6094, 1995.
Garcin et al., “A Point Mutation in the Sendai Virus Accessory C Proteins Attenuates Virulence for Mice, But Not Virus Growth in Cell Culture,”Virology238:424-431, 1997, Copy Enclosed.
Grosfeld et al., “RNA Replication by Respiratory Syncytial Virus (RSV) Is Directed by the N, P, and L Proteins; Transcription Also Occurs under These Conditions but Requires RSV Superinfection for Efficient Synthesis of Full-Length mRNA,”J. Virol. 69: 5677-5686, 1995.
Hall et al., “Cold-passaged Human Parainfluenza Type 3 Viruses Containtsand Non-tsMutations Leading to Attenuation in Rhesus Monkeys,”Virus Res. 22:173-184, 1992.
Hasan et al., “Creation of an Infectious Recombinant Sendai Virus Expressing the Firefly Luciferase Gene from the 3′ Proximal First Locus,”J. Gen. Virol. 78:2813-20, 1997, Copy Enclosed.
He et al., “Recovery of Infectious SV5 from Cloned DNA and Expression of a Foreign Gene,”Virology237:249-260, 1997, Copy Enclosed.
Hoffman et al., “An Infectious Clone of Human Parainfluenza Virus Type 3,”J. Virol. 71:4272-4277, 1997, Copy Enclosed.
Itoh et al., “Isolation of an Avirulent Mutant of Sendai Virus with Two Amino Acid Mutations from a Highly Virulent Field Strain Through Adaption to LLC-MK2Cells,”J. Gen. Virol. 78:3207-3215, 1997, Copy Enclosed.
Jin et al., “Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV,”Virology251:206-214, 1998, Copy Enclosed.
Johnson et al., “Specific Targeting to CD4+ Cells of Recombinant Vesicular Stomatitis Viruses Encoding Human Immunodeficiency Virus Envelope Proteins,”J. Virol. 71:5060-5068, 1997, Copy Enclosed.
Juhasz et al., “The Temperature-Sensitive (ts) Phenotype of a Cold-Passaged (cp) Live Attenuated Respiratory Syncytial Virus Vaccine Candidate, Designatedcpts530, Results from a Single Amino Acid Substitution in the L Protein,”J. Virol. 71:5814-5819, 1997.
Kahn et al., “Recombinant Vesicular Stomatitis Virus Expressing Respiratory Syncytial Virus (RSV) Glycoproteins: RSV Fusion Protein Can Mediate Infect
Collins Peter L.
Durbin Anna P.
Murphy Brian R.
Skiadopoulos Mario H.
Tao Tao
Chen Stacy B.
The United States of America as represented by the Department of
LandOfFree
Use of recombinant live-attenuated parainfluenza virus (PIV)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of recombinant live-attenuated parainfluenza virus (PIV)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of recombinant live-attenuated parainfluenza virus (PIV)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3946893